BridgeBio Pharma, Inc. Director's Stock Transactions

On August 5, 2025, Andrea Ellis, a director of BridgeBio Pharma, Inc., engaged in several transactions involving the company's common stock and stock options. Ellis exercised stock options to acquire 17,167 shares of common stock at an exercise price of $16.75 per share. Additionally, Ellis sold 17,167 shares of common stock at a price of $49 per share. These transactions were executed pursuant to a Rule 10b5-1 sales plan adopted by Ellis on December 30, 2024. Following these transactions, Ellis's total holdings in BridgeBio Pharma, Inc. common stock decreased to 18,589 shares. The stock options, which vest in three annual installments from June 21, 2024, through June 21, 2026, are subject to Ellis's continued service on the company's board of directors.